UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) October 30, 2017


NUTRA PHARMA CORP.

(Exact name of registrant as specified in its charter)


California

 

000-32141

 

91-2021600

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)


12538 West Atlantic Blvd
Coral Springs, Florida

 

33071

(Address of principal executive offices)

 

(Zip Code)


Registrant’s telephone number, including area code: (954) 509-0911


Registrant’s facsimile number, including area code: (877) 895-5647


Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging Growth Company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨




ITEM 3.02     Unregistered Sale of Equity Securities


ITEM 5.01     Changes in Control of Registrant


ITEM 5.03     Amendment to the Articles of Incorporation or Bylaws; Change in Fiscal Year


Effective October 30, 2017, Nutra Pharma Corporation (“Nutra Pharma” or the “Corporation”) pursuant to authority of its Board of Directors, filed a Certificate of Determination for its Series A Preferred Stock. The Series A Preferred Stock consists of 3,000,000 shares. The Series A Preferred Stock will vote with the Corporation’s common stock as a single class on all matters or consents for the Corporation’s common stockholders. Each share of Series A Preferred Stock is entitled to one thousand votes per share.


The Series A Preferred Stock was issued to Rik J. Deitsch, the Corporation’s Chairman, to discharge four hundred thousand dollars ($400,000) of Mr. Deitsch’s loan to the Corporation. Upon issuance of the Series A Preferred Stock Mr. Deitsch will own 62.7% of the Corporation’s voting stock.


The above is a summary of the Series A Preferred Stock. The full terms of the Series A Preferred Stock as set forth in the Certificate of Determination filed as Exhibit 3.1 hereto and incorporated by reference.


ITEM 9.01     Financial Statements and Exhibits


Exhibit No.

 

Exhibit Description

3.1

 

Certificate of Determination for the Series A Preferred Stock dated October 30, 2017



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Date: November 3, 2017

NUTRA PHARMA CORP.

 

By:

/s/ Rik J. Deitsch

 

 

Name:  

Rik J. Deitsch

 

 

Title:  

Chief Executive Officer/Director




EXHIBIT INDEX


Exhibit No.

 

Exhibit Description

3.1

 

Certificate of Determination for the Series A Preferred Stock dated October 30, 2017






Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Nutra Pharma (CE) Charts.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Nutra Pharma (CE) Charts.